Boston Scientific (NYSE:BSX) Stock Rating Lowered by TD Cowen

Boston Scientific (NYSE:BSX) was downgraded by stock analysts at TD Cowen from a “buy” rating to a “hold” rating in a research note issued on Friday, MarketBeat Ratings reports. They currently have a $46.00 price objective on the medical equipment provider’s stock. TD Cowen‘s target price indicates a potential upside of 7.76% from the company’s previous close.

A number of other brokerages have also recently issued reports on BSX. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Boston Scientific in a report on Friday, October 2nd. Needham & Company LLC decreased their price target on Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Evercore dropped their price objective on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a research note on Wednesday, October 7th. Finally, Citigroup reduced their price objective on Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.53.

Boston Scientific Stock Performance

Shares of BSX opened at $42.69 on Friday. The company has a 50-day simple moving average of $44.93 and a 200-day simple moving average of $57.15. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $61.86 billion, a PE ratio of 18.09, a P/E/G ratio of 1.04 and a beta of 0.58. Boston Scientific has a 52-week low of $39.57 and a 52-week high of $105.65.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.75 earnings per share. Equities research analysts predict that Boston Scientific will post 3.18 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director David Habiger bought 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 189,522 shares of company stock valued at $9,157,810 over the last 90 days. 0.34% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of BSX. BlackRock Inc. acquired a new position in shares of Boston Scientific in the second quarter worth $5,534,781,000. Primecap Management Co. CA acquired a new stake in shares of Boston Scientific during the second quarter valued at $2,156,233,000. Jupiter Topco LLC purchased a new stake in Boston Scientific during the 2nd quarter worth about $803,357,000. Bank of America Corp DE purchased a new stake in Boston Scientific during the 2nd quarter worth about $556,026,000. Finally, Legal & General Group Plc acquired a new position in Boston Scientific in the 2nd quarter valued at about $431,890,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of approximately $5.14 billion, ahead of consensus estimates, while adjusted EPS of $0.73 matched expectations. The results extended the company’s record of solid quarterly execution, although year-over-year EPS declined from $0.75. Boston Scientific Q3 Earnings Match Estimates
• Positive Sentiment: Some analysts continue to see long-term value. BTIG, Needham, UBS and Baird retained positive ratings, while Baird raised its target to $51. However, Needham, UBS and BTIG all reduced their targets, reflecting more cautious assumptions. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Management remains confident in Boston Scientific’s long-term strategy and expects a potential growth trough in 2027 followed by expansion toward 2030. That longer-term narrative is being weighed against substantial near-term execution risks. Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance
• Negative Sentiment: The cybersecurity outage lasted about eight days and reduced third-quarter sales by roughly $150 million. The disruption continues to affect operations, customer activity and the recovery timeline. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Boston Scientific cut its full-year 2026 adjusted EPS outlook to $3.16–$3.18, below investor expectations, and forecast fourth-quarter EPS of $0.77–$0.79. Fourth-quarter sales could decline year over year, intensifying concerns about weaker momentum. Boston Scientific Cuts View Again After Cyberattack
• Negative Sentiment: Analysts have become more cautious: JPMorgan downgraded BSX from overweight to neutral with a $46 target, Oppenheimer moved from outperform to market perform, and Wells Fargo lowered its target to $45. Concerns include weakness in electrophysiology and WATCHMAN products, China pricing pressure and potentially flat growth in 2027. Boston Scientific Stock Gets Downgrade from JPMorgan

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.